Developing novel lentiviral vectors into clinical products

Anna Leath, Kenneth Cornetta

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Gene therapy vectors based on murine retroviruses have now been in clinical trials for over 20 years. During that time, a variety of novel vector pseudotypes were developed in an effort to improve gene transfer. Lentiviral vectors are now in clinical trials and a similar evolution of vector technology is anticipated. These modifications present challenges for those producing large-scale clinical materials. This chapter discusses approaches to process development for novel lentiviral vectors, highlight considerations, and methods to be incorporated into the development schema.

Original languageEnglish
Pages (from-to)89-108
Number of pages20
JournalMethods in Enzymology
Volume507
DOIs
StatePublished - 2012

Fingerprint

Clinical Trials
Retroviridae
Genetic Therapy
Technology
Gene transfer
Gene therapy
Genes

Keywords

  • Clinical vector production
  • Gene therapy vectors
  • Lentiviral vectors
  • Replication competent lentivirus
  • Vector certification
  • Vector pseudotypes

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this

Developing novel lentiviral vectors into clinical products. / Leath, Anna; Cornetta, Kenneth.

In: Methods in Enzymology, Vol. 507, 2012, p. 89-108.

Research output: Contribution to journalArticle

@article{2ea16cc0da9346dabdbacaf02f40bcb4,
title = "Developing novel lentiviral vectors into clinical products",
abstract = "Gene therapy vectors based on murine retroviruses have now been in clinical trials for over 20 years. During that time, a variety of novel vector pseudotypes were developed in an effort to improve gene transfer. Lentiviral vectors are now in clinical trials and a similar evolution of vector technology is anticipated. These modifications present challenges for those producing large-scale clinical materials. This chapter discusses approaches to process development for novel lentiviral vectors, highlight considerations, and methods to be incorporated into the development schema.",
keywords = "Clinical vector production, Gene therapy vectors, Lentiviral vectors, Replication competent lentivirus, Vector certification, Vector pseudotypes",
author = "Anna Leath and Kenneth Cornetta",
year = "2012",
doi = "10.1016/B978-0-12-386509-0.00005-3",
language = "English",
volume = "507",
pages = "89--108",
journal = "ImmunoMethods",
issn = "1046-2023",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Developing novel lentiviral vectors into clinical products

AU - Leath, Anna

AU - Cornetta, Kenneth

PY - 2012

Y1 - 2012

N2 - Gene therapy vectors based on murine retroviruses have now been in clinical trials for over 20 years. During that time, a variety of novel vector pseudotypes were developed in an effort to improve gene transfer. Lentiviral vectors are now in clinical trials and a similar evolution of vector technology is anticipated. These modifications present challenges for those producing large-scale clinical materials. This chapter discusses approaches to process development for novel lentiviral vectors, highlight considerations, and methods to be incorporated into the development schema.

AB - Gene therapy vectors based on murine retroviruses have now been in clinical trials for over 20 years. During that time, a variety of novel vector pseudotypes were developed in an effort to improve gene transfer. Lentiviral vectors are now in clinical trials and a similar evolution of vector technology is anticipated. These modifications present challenges for those producing large-scale clinical materials. This chapter discusses approaches to process development for novel lentiviral vectors, highlight considerations, and methods to be incorporated into the development schema.

KW - Clinical vector production

KW - Gene therapy vectors

KW - Lentiviral vectors

KW - Replication competent lentivirus

KW - Vector certification

KW - Vector pseudotypes

UR - http://www.scopus.com/inward/record.url?scp=84857580568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857580568&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-386509-0.00005-3

DO - 10.1016/B978-0-12-386509-0.00005-3

M3 - Article

C2 - 22365770

AN - SCOPUS:84857580568

VL - 507

SP - 89

EP - 108

JO - ImmunoMethods

JF - ImmunoMethods

SN - 1046-2023

ER -